Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Diacrin, Inc. (NasdaqNM:DCRN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
Building 96 13th Street
Charlestown Navy Yard
Charlestown, MA 02129
Phone: (617) 242-9100
Fax: (617) 242-0070
Email: kkerrigan@diacrin.com
Employees (last reported count): 38
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 72%
·Institutional: 33% (120% of float)
(32 institutions)
·Net Inst. Selling: 66.0K shares (+1.11%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Diacrin, Inc. is developing cell transplantation technology for treating human diseases that are characterized by cell dysfunction or cell death, and for which current therapies are either inadequate or nonexistent. The Company's products under development include the NeuroCell-PD for Parkinson's disease; porcine neural cells for stroke, focal epilepsy and chronic intractable pain; porcine spinal cord cells for spinal cord injury; NeuroCell-HD for Huntington's disease; human liver cells for cirrhosis; porcine liver cells for acute liver failure; human muscle cells for cardiac disease; and porcine retinal pigment epithelial cells (porcine RPE cells) for muscular degeneration.
More from Market Guide: Expanded Business Description

Financial Summary
DCRN is developing proprietary populations of trans-plantable porcine cells for the treatment of human diseases which are characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent. For the three months ended 3/31/01, revenues rose 50% to $1.3 million. Net loss fell 35% to $811 thousand. Revenues reflect an increase in interest income. Net loss was partially offset by increased research and development expenses.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 990; after tax earnings were -1,334. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Thomas Fraser, Ph.D., 53
Pres, CEO
$295K
E. Michael Egan, 47
COO
220K
Kevin Kerrigan, 29
Controller
--  
Albert Edge, P.h.D., 47
senior director of molecular and cellular biology
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:DCRNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 10-Apr-2001
$1.08 
Recent Price$1.80 
52-Week High
on 5-Sep-2000
$9.125
Beta0.77 
Daily Volume (3-month avg)24.4K
Daily Volume (10-day avg)12.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-79.8%
52-Week Change
relative to S&P500
-72.8%
Share-Related Items
Market Capitalization$32.2M
Shares Outstanding17.9M
Float5.00M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$2.96 
Earnings (ttm)-$0.20 
Earnings (mrq)-$0.07 
Sales (ttm)$0.29 
Cash (mrq*)$2.00 
Valuation Ratios
Price/Book (mrq*)0.61 
Price/EarningsN/A 
Price/Sales (ttm)6.27 
Income Statements
Sales (ttm)$5.22M
EBITDA (ttm*)-$1.62M
Income available to common (ttm)-$3.63M
Profitability
Profit Margin (ttm)-69.4%
Operating Margin (ttm)-33.0%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-6.49%
Return on Equity (ttm)-6.70%
Financial Strength
Current Ratio (mrq*)23.55 
Debt/Equity (mrq*)0.00 
Total Cash (mrq)$52.3M
Short Interest
As of 8-Aug-2001
Shares Short2,000 
Percent of Float0.0%
Shares Short
(Prior Month)
4,000 
Short Ratio0.10 
Daily Volume21.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.